GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » EV-to-FCF

NRX Pharmaceuticals (STU:B1Q) EV-to-FCF : -2.60 (As of May. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NRX Pharmaceuticals's Enterprise Value is €46.28 Mil. NRX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-17.79 Mil. Therefore, NRX Pharmaceuticals's EV-to-FCF for today is -2.60.

The historical rank and industry rank for NRX Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:B1Q' s EV-to-FCF Range Over the Past 10 Years
Min: -2.65   Med: 0   Max: 0
Current: -2.45

STU:B1Q's EV-to-FCF is ranked worse than
100% of 370 companies
in the Biotechnology industry
Industry Median: 9.66 vs STU:B1Q: -2.45

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), NRX Pharmaceuticals's stock price is €4.88. NRX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.222. Therefore, NRX Pharmaceuticals's PE Ratio for today is At Loss.


NRX Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for NRX Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals EV-to-FCF Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -6.74 -1.62 -1.99

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -1.28 -0.86 -1.99 -2.68

Competitive Comparison of NRX Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, NRX Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NRX Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's EV-to-FCF falls into.



NRX Pharmaceuticals EV-to-FCF Calculation

NRX Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=46.282/-17.789
=-2.60

NRX Pharmaceuticals's current Enterprise Value is €46.28 Mil.
NRX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NRX Pharmaceuticals  (STU:B1Q) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

NRX Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.88/-2.222
=At Loss

NRX Pharmaceuticals's share price for today is €4.88.
NRX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.222.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


NRX Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals (STU:B1Q) Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines